Shenzhen McKeton Bio-Medical Technology Co., Ltd. (McKeton) is a familiar contender in the queue for an IPO listing on the Hong Kong Stock Exchange. On March 11th, this medical device company, steered by a founding team with ties to "Mindray" and backed by Hillhouse Capital holding over 20%, resubmitted its application on the very day its first prospectus lapsed, aiming for a seamless transition. This renewed attempt not only presents updated financial data showing a crucial return to profitability for the full year 2025 but also reveals a latest valuation that has climbed to 8.245 billion RMB. However, behind this "platform-type" narrative rapidly constructed through acquisitions loom multiple concerns awaiting market scrutiny, including substantial goodwill, instability in its distributor channels, and compliance blemishes.
The prospectus indicates that continuous capital injection has served as the ammunition for McKeton's acquisition-driven expansion. Since 2017, the company has rapidly built three core business segments—life support, minimally invasive intervention, and in-vitro diagnostics—through a series of acquisitions. By the end of 2025, the company had commercialized 330 products, including 60 life support products, 110 minimally invasive intervention products, and 160 in-vitro diagnostic products, covering over 140 countries and regions globally, with overseas revenue accounting for 48%. Domestically, its products have cumulatively reached over 6,000 hospitals, approximately 90% of which are top-tier Class A Grade III hospitals, while more than 40 pipeline candidate products are still under development.
Following a share subscription completed in 2023, McKeton's post-investment valuation rose to 8.245 billion RMB, representing a roughly 24.77-fold increase from its Series A financing valuation of 320 million RMB in 2016, highlighting strong capital endorsement of its M&A integration strategy. Notably, McKeton also completed two rounds of share transfers in 2023 and 2024, raising 161 million RMB and 89.96 million RMB, respectively. As these rounds involved transfers of existing shares, they suggest the company's valuation has remained stable above the 8 billion RMB mark without significant fluctuation.
Observations indicate that successfully returning to profit in 2025 provides critical support for McKeton's second attempt to list in Hong Kong. However, a deeper analysis of its financial structure reveals a distinct dual nature—substantive improvement in profitability coexists with accumulating risks from post-acquisition side effects.
The positive side (A-side) lies in operational efficiency driving the profit inflection point. Regarding revenue quality, from 2023 to 2025, the company's revenue grew from 1.313 billion RMB to 1.619 billion RMB, with a 15.71% year-on-year increase in 2025, accelerating by 5.6 percentage points compared to the previous year. More significantly, the gross margin saw continuous optimization, steadily rising from 49.6% to 53.7% over the same period, a cumulative increase of 4.1 percentage points. This improvement exceeds what can be explained by mere revenue expansion, indicating a strategic shift towards higher value-added segments (such as an increased proportion of minimally invasive intervention consumables) and the realization of cost synergies from supply chain integration.
The breakthrough on the profit front is particularly noteworthy. After accumulating net losses totaling 387 million RMB between 2022 and 2024, the company achieved a net profit of 50.738 million RMB in 2025. The adjusted net profit (excluding non-cash items like share-based payments and intangible asset amortization) reached 129 million RMB, corresponding to a net profit margin of 3.13%. This signifies that the company has crossed the threshold of "strategic losses," with operating cash flow expected to turn positive—a key indicator of a platform-based medical device company transitioning from the investment phase to the harvest phase.
The negative side (B-side) involves a potential profit "dam" created by high goodwill. The acquisition-driven growth model is exposing the company to significant risk. As of the end of 2025, the book value of goodwill, stemming from acquisitions such as UK-based Penlon, Jiangsu Weidekang Medical, and Vedefar, stood as high as 928 million RMB, accounting for 49.47% of the net assets (1.876 billion RMB) for the same period. Notably, the acquisition of Weidekang Medical alone contributed 914 million RMB in goodwill, representing 98.5% of the total, creating a highly concentrated source of impairment risk.
Although the company employs a "gradual integration" strategy to manage acquired entities, and both Penlon and Weidekang Medical have maintained growth in gross profit in recent years, early risk indicators are emerging. Firstly, Penlon's operations have decelerated, with revenue declining 16.41% year-on-year in 2025, falling below 2023 levels, suggesting that synergies in the anesthesia and respiratory access fields have not yet been fully realized. Secondly, dependence on Weidekang has intensified. The minimally invasive intervention business, led by Weidekang, has become the company's largest revenue source, accounting for 50% of total revenue in 2025. This means over half of the company's revenue relies on a single acquisition target. Should its future growth slow, core products face price reductions, or market competition intensify, it could create a double blow to the consolidated financial statements—impacting both the revenue line and potentially triggering goodwill impairment, directly eroding current profits.
The prospectus shows that McKeton's business structure has undergone strategic reshaping over the past three years. The company has rapidly shifted from a balanced layout driven by "three pillars" to a growth model propelled primarily by a single core: minimally invasive intervention. In 2023, the life support and minimally invasive intervention segments were comparable in size (564 million RMB vs. 587 million RMB), jointly forming the company's foundation. By 2025, this landscape had fundamentally changed, with minimally invasive intervention becoming the absolute pillar. Revenue from this segment jumped from 587 million RMB to 812 million RMB, achieving a two-year compound annual growth rate of 17.7%. Its revenue share increased from 44.7% to 50.1%, now constituting half of the company's business.
The life support segment experienced significant volatility. Its revenue contracted to 494 million RMB in 2024 (a 12.4% year-on-year decrease). Although it rebounded to 613 million RMB in 2025, it has not yet established a stable growth trajectory. The diagnostics segment, traditionally a cash cow, saw revenue grow from 163 million RMB to 194 million RMB, with a two-year CAGR of only 9.2%, lagging significantly behind the industry average and showing signs of falling behind.
In essence, McKeton is no longer a platform-based company with a tripartite balance among life support, minimally invasive intervention, and in-vitro diagnostics. It has transformed into a specialized medical device company highly dependent on minimally invasive intervention. The effects of the Weidekang Medical acquisition are clearly materializing, but this also means the company's fate is deeply intertwined with the dynamics of the digestive endoscopy market. The forthcoming test is whether this "single core" can pull the other segments out of their struggles to achieve genuine, comprehensive profitability.
McKeton's evolution from "three pillars" to "single-core driven" growth clearly reflects a typical paradigm for Chinese medical device companies seeking leapfrog development through acquisitions. The consolidation of Weidekang Medical has not only underpinned the multi-billion RMB valuation but also pushed the company to a profitability inflection point—the return to profit in 2025 marks a transition from the capital-intensive "investment phase" of M&A integration to the critical juncture of the "realization phase." However, the other side of the coin cannot be ignored: 928 million RMB in goodwill hangs overhead, over half of revenue hinges on a single acquisition target, and the life support and diagnostics segments show weak growth. As "Weidekang dependency" becomes a core variable in the company's fundamentals, any policy shifts or intensified competition within its key market could trigger significant volatility in the profit and loss statement.
Comments